In patients with hemophilia A with inhibitors, a novel therapy called emicizumab decreases incidence of bleeding episodes by 87 percent, an international team of hematologists has found.
In patients with hemophilia A with inhibitors, a novel therapy called emicizumab decreases incidence of bleeding episodes by 87 percent, an international team of hematologists has found.